Choose your kidney diagnosis to see recently approved treatments and actively enrolling clinical trials for that condition — with plain-language evidence and links to ClinicalTrials.gov.
For information only — not medical advice. Always talk to your nephrologist.
17 FDA-approved therapies since 2018 — 8 in the last two years — plus 3 trials enrolling now.
New U.S. FDA approvals for a kidney indication, by year — across IgA nephropathy, lupus nephritis, C3 glomerulopathy, FSGS, diabetic and polycystic kidney disease, and more. Sources on each treatment card below. Verified July 2026.
Blood-pressure control with ACE inhibitors or ARBs, and SGLT2 inhibitors, are standard first-line therapy for most CKD. Your nephrologist typically starts here.
These are newer and recently approved therapies for APOL1-mediated kidney disease — not the full standard of care. Ask your care team whether any fit your situation.
No FDA-approved therapies we're tracking specifically for APOL1-mediated kidney disease yet. A nephrologist can advise on the best options.
Actively enrolling studies related to APOL1-mediated kidney disease. Whether a trial is right for you — and whether you qualify — is decided by the study team together with your nephrologist.
Testing an oral APOL1 channel inhibitor in people with two APOL1 variants and proteinuric kidney disease. Phase 2a showed a 47.6% proteinuria reduction at 13 weeks.
Eligibility is determined by the study team and your nephrologist.
View the AMPLITUDE on ClinicalTrials.govSource: Inaxaplin Phase 2a, NEJM 2023 (Vertex)Verified 2026-07-18
For information only — this is not medical advice, and nothing here is a recommendation to start, stop, or switch treatment. Every treatment decision should go through your nephrologist.
Jump straight to treatments and enrolling trials for a specific kidney diagnosis.
Lutango helps you track labs, meals, fluids, blood pressure, medications, and more — built specifically for chronic kidney disease.
Get started free